MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock upon...
$539,585K
Proceeds from exercise of
stock options
$20,544K
Proceeds from issuance of
common stock pursuant...
$1,592K
Net cash provided by
financing activities
$561,721K
Net increase in
cash, cash...
$344,958K
Canceled cashflow
$216,763K
Stock-based compensation
expense
$43,184K
Accrued expenses
$5,248K
Depreciation and
amortization expense
$4,323K
Non-cash interest
expense
$3,397K
Prepaid expenses and
other current assets
-$2,602K
Change in fair value of
derivative liabilities
-$2,471K
Accounts receivable, net
-$1,738K
Operating lease assets
-$1,307K
Proceeds from sales of
property and equipment
$130K
Net cash used in
operating activities
-$204,883K
Net cash used in
investing activities
-$11,880K
Canceled cashflow
$64,270K
Canceled cashflow
$130K
Revenue
$51,951K
Interest income
$18,355K
Net loss
-$265,939K
Purchases of property and
equipment
$12,010K
Canceled cashflow
$70,306K
Operating lease
liabilities
-$1,646K
Accounts payable
-$887K
Inventory
$524K
Deferred revenue
-$128K
Gains and losses on
disposal of items of...
$29K
Direct program
expenses, axpaxli for wet...
$119,609K
Selling & marketing
$48,510K
Stock-based compensation
$43,184K
Unallocated expenses,
personnel costs
$39,255K
General &
administrative
$37,377K
Interest expense
$11,835K
Unallocated expenses, all
other costs
$7,527K
Facilities
$7,223K
Cost of product
revenue
$6,574K
Direct program
expenses, axpaxli for npdr
$4,804K
Depreciation
$4,323K
Direct program
expenses, other clinical...
$3,582K
Other non-operating
items
-$2,442K
Back
Back
Cash Flow
source: myfinsight.com
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)